March 21, 1964

Mr. Harold R. Hamilton
Clinical Coordinator
Neisler Laboratories, Inc.
1800 East Pershing Road
Decatur, Illinois

Dear Mr. Hamilton:

My associates and I have had an opportunity to discuss the compound, IN-379, and find it of considerable interest to us. I believe that it may be possible for us to undertake a pilot investigation in a small number of patients, using both clinical and electroencephalographic parameters, in order to define an answer to the question of whether IN-379 posesses psychotropic activity.

To do so, requires the development of a suitable protocol, approval by the Institute Pharmacology Committee, and the assignment of a staff member to undertake the project. In order to provide a definitive answer, it will be necessary not only to undertake the clinical studies outlined, but also to provide some protection of our patients by providing suitable laboratory safeguards.

It may be possible to begin this study early in June, since we will first have to scan our population and find a reasonable sample. Since the transfer of patients to our wards may, in and of itself, have a salutary effect, we shall have to undertake the transfer first and allow a suitable period of observation before this compound is introduced.

Because of this factor, and the expectation that the drug therapy period will be a minimum of three months, I believe the full study will take a period of six to eight months. However, if you can supply us with some intravenous preparation, we will plan to undertake some preliminary observations in a laboratory setting to determine the behavioral, electrographic, and physiological effects of the acute administration of this compound.

Thus, I believe that we can undertake two separate studies - acute investigations in our laboratory, and a three month chronic investigational trial. Would you call me to discuss your participation in this study?

Sincerely yours,

Max Fink, M.D.
Director

MF/jb